Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: ValuEngine, Inc.
|
$127.00
|
|
Provider: Wright Reports
|
$472.00
|
|
Provider: Market Edge
|
$10.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Vivus, Inc. Announces Proposed Public Offering Of Common Stock
Vivus, Inc. announced that it is offering to sell, subject to market and other conditions, 8,500,000 shares of its common stock pursuant to an effective shelf registration statement in an underwritten public offering. VIVUS also intends to grant the underwriters a 30 day option to purchase up to an aggregate of 1,275,000 additional shares of common stock to cover over-allotments, if any. All of the shares in the offering are to be sold by VIVUS. J.P. Morgan Securities LLC is acting as sole book-running manager of the proposed offering.
Latest Developments for VIVUS Inc
- Vivus Inc Gets FDA Nod To Sell Diet Pill Via Retail Pharmacies-Reuters
- Vivus Inc Announces Study Finds Improvements In Patients With Obstructive Sleep Apnea Treated With Phentermine And Topiramate Extended-Release Capsules
- European Regulators Reject Vivus Inc Obesity Drug-Reuters
- Vivus Inc Announces FDA Approval of Once Daily Qsymia (Phentermine and Topiramate Extended-release) Capsules CIV
Latest Key Developments in Pharmaceuticals
- Novo Nordisk A/S Reports 8% Weight Loss in Phase 3a Obesity Trial with Liraglutide 3 mg
- Wai Yuen Tong Medicine Holdings Ltd Comments On FY 2013 Earnings Guidance
- BioPorto A/S Updates on NGAL Patent Processing of Appeal in Opposition Case
- Astellas Pharma Inc Receives Marketing Authorization for VESOMNI from The Netherlands Medicines Evaluation Board
- Share this
- Link this
- Digg this
Follow Reuters